Stroke

CLINICAL AND POPULATION SCIENCES

Endovascular Thrombectomy for Acute Ischemic Stroke Beyond 6 Hours From Onset

A Real-World Experience

Ilaria Casetta, MD; Enrico Fainardi, MD, PhD; Valentina Saia, MD, PhD; Giovanni Pracucci, MD; Marina Padroni, MD; Leonardo Renieri, MD; Patrizia Nencini, MD; Domenico Inzitari, MD; Daniele Morosetti, MD; Fabrizio Sallustio, MD; Stefano Vallone, MD; Guido Bigliardi, MD; Andrea Zini, MD; Marcello Longo, MD; Isabella Francalanza, MD; Sandra Bracco, MD; Ignazio M. Vallone, MD; Rossana Tassi, MD; Mauro Bergui, MD; Andrea Naldi, MD; Andrea Saletti, MD; Alessandro De Vito, MD; Roberto Gasparotti, MD; Mauro Magoni, MD; Lucio Castellan, MD; Carlo Serrati, MD; Roberto Menozzi, MD; Umberto Scoditti, MD; Francesco Causin, MD; Alessio Pieroni, MD; Edoardo Puglielli, MD; Alfonsina Casalena, MD; Antioco Sanna, MD; Maria Ruggiero, MD; Francesco Cordici, MD; Luca Di Maggio, MD; Enrica Duc, MD; Mirco Cosottini, MD; Nicola Giannini, MD; Giuseppina Sanfilippo, MD; Federico Zappoli, MD; Anna Cavallini, MD; Nicola Cavasin, MD; Adriana Critelli, MD; Elisa Ciceri, MD; Mauro Plebani, MD; Manuel Cappellari, MD; Luigi Chiumarulo, MD; Marco Petruzzellis, MD; Alberto Terrana, MD; Lucia Princiotta Cariddi, MD; Nicola Burdi, MD; Angelica Tinelli, MD; William Auteri, MD; Umberto Silvagni, MD; Francesco Biraschi, MD; Ettore Nicolini, MD; Riccardo Padolecchia, MD; Tiziana Tassinari, MD; Pietro Filauri, MD; Simona Sacco, MD; Marco Pavia, MD; Paolo Invernizzi, MD; Nunzio P. Nuzzi, MD; Simona Marcheselli, MD; Pietro Amistà, MD; Monia Russo, MD; Ivan Gallesio, MD; Giuseppe Craparo, MD; Marina Mannino, MD; Salvatore Mangiafico, MD; Danilo Toni, MD; on behalf of the Italian Registry of Endovascular Treatment in Acute Stroke

BACKGROUND AND PURPOSE: To evaluate outcome and safety of endovascular treatment beyond 6 hours of onset of ischemic stroke due to large vessel occlusion in the anterior circulation, in routine clinical practice.

METHODS: From the Italian Registry of Endovascular Thrombectomy, we extracted clinical and outcome data of patients treated for stroke of known onset beyond 6 hours. Additional inclusion criteria were prestroke modified Rankin Scale score ≤2 and ASPECTS score ≥6. Patients were selected on individual basis by a combination of CT perfusion mismatch (difference between total hypoperfusion and infarct core sizes) and CT collateral score. The primary outcome measure was the score on modified Rankin Scale at 90 days. Safety outcomes were 90-day mortality and the occurrence of symptomatic intracranial hemorrhage. Data were compared with those from patients treated within 6 hours.

RESULTS: Out of 3057 patients, 327 were treated beyond 6 hours. Their mean age was 66.8±14.9 years, the median baseline National Institutes of Health Stroke Scale 16, and the median onset to groin puncture time 430 minutes. The most frequent site of occlusion was middle cerebral artery (45.1%). Functional independence (90-day modified Rankin Scale score, 0–2) was achieved by 41.3% of cases. Symptomatic intracranial hemorrhage occurred in 6.7% of patients, and 3-month case fatality rate was 17.1%. The probability of surviving with modified Rankin Scale score, 0–2 (odds ratio, 0.58 [95% CI, 0.43–0.77]) was significantly lower in patients treated beyond 6 hours as compared with patients treated earlier No differences were found regarding recanalization rates and safety outcomes between patients treated within and beyond 6 hours. There were no differences in outcome between people treated 6-12 hours from onset (278 patients) and those treated 12 to 24 hours from onset (49 patients).

CONCLUSIONS: This real-world study suggests that in patients with large vessel occlusion selected on the basis of CT perfusion and collateral circulation assessment, endovascular treatment beyond 6 hours is feasible and safe with no increase in symptomatic intracranial hemorrhage.

Key Words: cerebral blood volume ■ collateral circulation ■ groin ■ intracranial hemorrhage ■ middle cerebral artery ■ thrombectomy

Correspondence to: Ilaria Casetta, MD, Clinica Neurologica, University of Ferrara, Via Aldo Moro 8, 44124 Cona/Ferrara, Italy. Email cti@unife.it

The Data Supplement is available with this article at https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.119.027974.

The registry organization and participating centers are available in the Data Supplement.

For Sources of Funding and Disclosures, see page 2056.

Stroke is available at www.ahajournals.org/journal/str

Randomized controlled trials (RCTs) on acute ischemic stroke (AIS) due to large vessel occlusion (LVO) established the superiority of endovascular thrombectomy (EVT) in addition to the best medical management, including intravenous thrombolysis, over best medical management alone within 6 hours from symptom onset.[1–6] Some of these trials enrolled patients up to 8[5] or 12 hours[2] from symptom onset. The HERMES collaboration individual patient data meta-analyses[7,8] of the first 5 RCTs[1–5] showed that the probability of functional independence (modified Rankin Scale [mRS], 0–2) at 3 months was 46.1%,[7] and that although the magnitude of benefit declines as time from symptom onset to groin puncture increases, the treatment benefit also remains beyond 6 hours after stroke onset, but it becomes nonsignificant after 7.3 hours.[8]

More recent trials demonstrated that the time window for endovascular treatment can be extended up to 16[9] or 24 hours[10] from the last time the patient was known to be well, when the selection is based on neuroimaging evaluation showing a salvageable penumbra[9] or a mismatch between clinical deficit and infarct size.[10] As a result, current guidelines[11,12] recommend thrombectomy in the 6- to 24-hour time window for patients meeting the DAWN[10] and DEFUSE-3 trial[9] criteria. The DAWN and DEFUSE-3 trials[9,10] focused on patients who suffered mainly from unwitnessed or wake-up stroke. Only 10% of treated patients and 14% of control patients in the DAWN study[10] and 34% and 39% of patients and controls, respectively, in the DEFUSE-3 trial[9] were treated beyond 6 hours after witnessed stroke onset.

The aim of this study is to evaluate the outcome and safety of EVT in patients with anterior circulation AIS due to a proximal intracranial artery occlusion who were treated beyond 6 hours from known symptom onset in a large real-world cohort of patients included in the Italian Registry of Endovascular Thrombectomy.

METHODS

The source of data is the Italian Registry of Endovascular Stroke Treatments, a multicenter, prospective, observational internet-based registry which includes patients treated with thrombectomy since 2011. The purposes, organization, and structure of the Registry were previously described in more detail.[13,14] This registry was implemented to collect baseline and outcome information for all treated patients and to share experiences and operational protocols, with the aim to improve and standardize quality of care delivered throughout the national territory. Centers included in the registry were required to accept the rules of the registry, including consecutive registration of all patients with stroke receiving endovascular procedures, participation in regular meetings, and incorporation of the proposed operational protocols in their routine local practice. The data that support the findings of this study are available from the corresponding author upon reasonable request. Ethical approval from the ethics committees of the participating centers and patient informed consent were obtained. According to national guidelines,[15] patients admitted within 6 hours of stroke onset were considered eligible for endovascular treatment if the following inclusion criteria were fulfilled: LVO documented on CT angiography (CTA), a baseline CT Alberta Stroke Program Early CT Score (ASPECTS) ≥6, and a prestroke mRS score ≤2. However, in selected patients, endovascular procedure was conducted beyond 6 hours after stroke onset. The decision to treat beyond the standard therapeutic window was individualized on the basis of findings obtained from admission brain noncontrast CT scans, CTA of cervical vessels, head single-phase CTA or preferably, multi-phase CTA of intracranial vessels and CT perfusion (CTP). The extension of early ischemic changes was evaluated on noncontrast CT by using ASPECTS. Collateral supply was graded on a 4-point scale for single-phase CTA,[16] in which collaterals were categorized as poor (scores, 0–1) and good (scores, 2–3), and on a 6-point scale for multi-phase CTA, in which collaterals were classified as poor (grade, 0–3) and good (scores, 4–5).[17] Cerebral blood flow, cerebral blood volume, and mean-transit-time CTP maps were generated for each patient. CTP was evaluated according to the classical CTP mismatch model[18]: (1) mean-transit-time lesion indicating total hypoperfusion; (2) cerebral blood volume lesion referring to infarct core; and (3) mean-transit-time-cerebral blood volume representing ischemic penumbra. CTP mismatch was defined as the difference between total hypoperfusion and infarct core size and was evaluated by visual inspection. For each modality, patients were judged to be candidates for EVT based on the following criteria: (1) noncontrast CT ASPECTS ≥6; (2) good collateral circulation (single-phase CTA collateral score of 2–3 or multi-phase CTA collateral score of 4–5); (3) CTP mismatch with an infarct core size ≤50% of total hypoperfusion extent or involving less than one-third of the MCA territory extent according to Turk et al[19] and to mismatch ratio model. Patients with noncontrast CT ASPECTS <6, with poor collaterals, without CTP mismatch or with CTP mismatch but an infarct core size >50% of total hypoperfusion extent or involving more than one-third of the MCA territory extent, with an inability to complete multimodal CT protocol at baseline or with poor CT quality were excluded. The same inclusion and exclusion criteria were also used for the selection of patients treated with endovascular therapy within 6 hours of stroke onset. We extracted data for patients with LVO (occlusion of the internal carotid artery, and middle cerebral artery M1 or M2), treated within and beyond 6 hours of stroke onset between 2011 and 2017. Patients with an occlusion of middle cerebral artery M3, anterior cerebral artery, or the posterior circulation were excluded. To include only cases definitely treated beyond 6 hours, patients with unknown onset of stroke (due to patients being unconscious, disoriented or aphasic, when a witness was not available, or when the patient awoke with stroke symptoms) were excluded from this analysis. For each patient, demographics, stroke risk factors, prestroke mRS, stroke severity (National Institutes of Health Stroke Scale [NIHSS] at admission), baseline neuroimaging, and data on endovascular treatment were collected. Clinical follow-up was assessed by mRS at 3 months. The primary outcome measure was the score on mRS at 90 days, as assessed by a local trained neurologist through in-person visit, or through a phone standardized interview when a face-to-face assessment was not possible. We examined the following dichotomizations of the mRS score: 0 to 1 versus 2 to 6, 0 to 2

versus 3 to 6, and 0 to 3 versus 4 to 6. For efficacy measures, arterial recanalization was rated according to the Thrombolysis in Cerebral Infarction (TICI) score.[20] Successful recanalization was defined as TICI score 2b or 3, while TICI 3 defined as complete recanalization. Symptomatic intracranial hemorrhage (sICH) was defined as any intracranial hemorrhage associated with a 4 point increase in the 24 hours NIHSS score, according to the ECASS II definition.[21] SICH, procedural adverse events (subarachnoid hemorrhage and vessel dissection), and death rate were considered safety measures.

Statistical Analysis

Data were presented as absolute numbers, percentages, mean±SD if normally distributed or median and interquartile ranges, as appropriate. Dichotomous variables were compared using the χ^2 test, while continuous variables were compared by Student *t* test or Mann-Whitney *U* test as appropriate on the basis of data distribution. A multivariable logistic regression analysis to adjust for sex, age, history of hypertension, diabetes mellitus, dyslipidemia, atrial fibrillation, smoking status (current or former), NIHSS score at entry, site of occlusion, and ASPECTS score, was also run to compare outcome and safety measures between subgroups of patients treated at different times. The functional outcome was further evaluated with ordinal logistic regression, taking the whole range of mRS into account as a dependent variable adjusted for the above variables. The adjusted common odds ratio (OR) and corresponding 95% CI for a shift in the direction of a better outcome on the modified Rankin scale was, therefore, calculated. A $P<0.05$ was considered significant for all tests.

RESULTS

Out of 3057 patients with AIS whose time at stroke onset was known, 327 (164 women and 163 men) treated beyond 6 hours after symptom onset were included in the analysis. Their mean age was 66.8±14.9 years. Good collaterals were identified by single-phase CTA in 209 and by multi-phase CTA in 118 patients. All patients had a CTP mismatch. Of these, infarct core size was considered ≤50% of total hypoperfusion extent in 174 and less than one-third the middle cerebral artery territory extent in 153 patients. Table 1 summarizes clinical and demographic data of included patients. The median NIHSS score at baseline was 16 (interquartile range, 12–20). The most frequent site of occlusion was the middle cerebral artery M1 (45%). The median onset-to-groin puncture time was 430 minutes (interquartile range, 390–570). Two hundred and one patients (61.5%) were treated between 361 and 480 minutes, 55 (16.8%) between 481 and 600 minutes, 22 patients (6.7%) between 601 and 720 minutes, and 49 patients (15%) beyond 12 hours (up to 24 hours) from symptoms onset. Functional independence (mRS, 0–2) at 90-day follow-up was achieved by 41.3% of cases (Table 2). The proportion of patients with stroke with complete recovery or minimal disability at 3 months (mRS, 0–1) was 26.9%, while 53.2% of patients survived with a disability range of 0 to 3. The 3-month case fatality rate was 17.1%. SICH occurred in 22 patients (6.7%). A successful recanalization was achieved in 232 patients (70.9%), while TICI score of 3 was recorded in 167 subjects (51.1%).

Table 1. Clinico-Demographic Characteristics, and Outcome of Patients Treated Within and Beyond 6 Hours

	Beyond 6 Hours	Within 6 Hours
Sex, men, n (%)	163 (49.8)	1352 (49.5)
Age, mean±SD	66.8±14.9*	69.73±13.7*
History, n/N (%)		
Hypertension	186/319 (58.3)	1625/2585 (62.9)
Diabetes mellitus	51/317 (16.1)	408/2585 (15.8)
Dyslipidemia	67/317 (21.1)	641/2585 (24.8)
Atrial fibrillation	92/318 (28.9)	878/2584 (34.0)
TIA/stroke (last 3 mo)	12/327 (3.6)	117/2720 (4.3)
Smokers	67/317 (21.1)	636/2585 (24.6)
History of malignancy	16/320 (5.0)	155/2725 (5.7)
Baseline NIHSS (median, IQR)	16, 12–20†	18, 13–21†
ASPECTS (median, IQR)	8, 7–10‡	9, 8–10‡
IV thrombolysis, n/N (%)	25/327 (27.6)§	1774/2730 (65.0)§
Onset to groin puncture time (median, IQR)	430 (390–570)*	220 (170–273)*
Site of occlusion n (%)	Total number 327‡	Total number 2730‡
Middle cerebral artery, proximal (M1)	147 (45.0)	1338 (49.0)
Middle cerebral artery, distal (M2)	43 (13.1)	421 (15.4)
Carotid T	52 (15.9)	446 (16.3)
Tandem occlusion	85 (26.0)†	525 (12.9)†

ASPECTS indicates Alberta Stroke Program Early CT Score; IQR, interquartile range; IVT, intravenous thrombolysis; NIHSS, National Institutes of Health Stroke Scale; and TIA, transient ischemic attack.
*$P<0.001$, †$P<0.01$, ‡$P<0.05$, §$P<0.0001$.

Outcomes by final TICI score are reported in Table 3.

When focusing on patients with internal carotid artery and M1 occlusion (excluding those with M2 occlusion), the findings concerning outcomes were not significantly different, since the proportions of patients with 90-day mRS 0 to 1, 0 to 2, and 0 to 3 were 25.4% (72/284), 39.1% (111/284), and 50.4% (143/284), respectively. Twenty-one patients (7.4%) had sICH, and the 3-month case fatality was 17.3% (49/284). Complete recanalization was achieved in 146 (51.4%) of patients, and TICI 2b/3 was recorded in 200 (70.4%).

We compared outcome data between patients who underwent EVT beyond 6 hours and patients with AIS treated within 6 hours of symptom onset extracted by the Italian Registry with the same selection criteria (Table 1). This population included 2730 patients (1352 men and 1378 women) with a mean age of 69.73±13.6 SD and a median NIHSS at baseline of 18 (interquartile range, 13–21).

Patients treated beyond 6 hours were significantly younger than patients treated earlier ($P<0.001$), had a lower baseline NIHSS score ($P<0.01$), and a lower

Table 2. Outcome and Safety Data

	Beyond 6 Hours (n=327)	Within 6 Hours (n=2730)	AdjOR (95% CI)
Shift analysis			1.57 (1.25–1.98)
Outcomes, n (%)			
mRS 0–1	88 (26.9)	908 (33.3)	0.52 (0.38–0.7)
mRS 0–2	135 (41.3)	1271 (46.6)	0.58 (0.43–0.77)
mRS 0–3	174 (53.2)	1617 (59.2)	0.59 (0.44–0.78)
Death	56 (17.1)	443 (16.2)	1.19 (0.8–1.7)
TICI 2b/3	232 (70.9)	1999 (73.2)	0.7 (0.6–1.01)
TICI 3	167 (51.1)	1505 (5.1)	0.78 (0.6–1.003)
sICH	22 (6.7)	189 (6.9)	0.97 (0.58–1.6)

Data on final recanalization were not available for 3 patients treated beyond 6 hours. AdjOR indicates odds ratio adjusted for age, sex, site of occlusion, baseline, stroke severity, atrial fibrillation, hypertension, diabetes mellitus, dyslipidemia, smoke; mRS, modified Rankin Scale; sICH, symptomatic intracranial hemorrhage; and TICI, Thrombolysis in Cerebral Infarction.

median ASPECTS score. No significant differences were found regarding vascular risk factors and comorbidities. A tandem occlusion was more frequent in patients treated later ($P<0.01$).

The comparison of outcomes in patients treated beyond and within 6 hours was reported in Table 2. The common adjusted OR for a shift toward a better outcome was 1.59 (1.27–2.02) in favor of patients treated earlier.

The multivariable logistic regression analysis showed that the probability of surviving with mRS 0 to 1 (OR, 0.52 [95% CI, 0.38–0.7]), mRS 0 to 2 (OR, 0.58 [95% CI, 0.43–0.77]), or mRS 0 to 3 (OR, 0.59 [95% CI, 0.44–0.78]) was significantly lower in patients treated beyond 6 hours. No differences were found regarding recanalization rates and safety outcomes.

We compared baseline characteristics and outcomes (Table 4) of patients treated between 6 and 12 hours and those treated beyond 12 hours. We found no significant differences between these 2 groups, except for a higher probability for survival with mRS 0 to 3 in the group of patients treated 6 to 12 hours after stroke onset.

Table 3. Outcome and Safety Data of Patients Treated Beyond 6 Hours According to Final TICI Score

	TICI 0	TICI 1	TICI 2a	TICI 2b	TICI 3
No. of patients	27	22	43	65	167
Outcome n (%)					
Death	11 (40.7)	8 (36.4)	5 (11.6)	10 (15.4)	20 (12)
sICH	0	2 (9.1)	3 (7)	6 (9.2)	10 (6)
3-month mRS					
mRS 0–1	1 (3.7)	2 (9.1)	7 (16.3)	18 (27.7)	60 (35.9)
mRS 0–2	3 (11.1)	3 (13.6)	19 (44.2)	22 (33.8)	88 (52.7)
mRS 0–3	6 (22.2)	6 (27.3)	26 (6.5)	30 (46.2)	106 (63.5)

Data on final recanalization were not available for 3 patients. mRS indicates modified Rankin Scale; TICI, Thrombolysis in Cerebral Infarction; and sICH, symptomatic intracranial hemorrhage.

Table 4. Demographic, Baseline Clinical Characteristics, Site of Occlusion, Interventional Workflow, and Outcome of Patients Treated Beyond 6 Hours, According to Onset to Groin Puncture Time

	6–12 Hours (n=278)	12–24 Hours (n=49)	AdjOR (95%CI)
Sex, men n (%)	135 (48.6)	28 (57.1)	
Age (mean±SD)	66.7 (15.2)	67.2 (13.1)	
History, n/N %			
Hypertension	159/273 (58.2)	27/46 (58.7)	
Diabetes mellitus	47/270 (17.4)	4/47 (8.5)	
Dyslipidemia	55/270 (20.4)	12/47 (25.4)	
Atrial fibrillation	82/271 (30.2)	10/47 (21.2)	
Smoker	56/270 (20.7)	11/47 (22.2)	
Median (IQR) baseline NIHSS	16 (12–20)	15.5 (10–22.75)	
Site of occlusion, n (%)			
M1	131 (47.1)	16 (32.7)	
M2	37 (13.3)	6 (12.2)	
Carotid T occlusion	43 (15.5)	9 (18.4)	
Tandem occlusion	67 (24.1)	18 (36.7)	
Median (IQR) time to groin puncture	420 (386.5–494)*	953 (826–1130)*	
Outcome, n (%)			
mRS 0–1	78 (28.1)	10 (20.4)	2 (0.8–4.9)
mRS 0–2	118 (42.4)	17 (34.7)	2 (0.9–4.3)
mRS 0–3	154 (55.4)	20 (40.8)	2.6 (1.2–5.5)
Death	47 (16.9)	9 (18.4)	1.04 (0.4–2.7)
TICI 2b/3	198 (71.2)	34 (69.4)	0.9 (0.4–1.9)
TICI 3	144 (51.8)	23 (46.9)	1.1 (0.5–2.2)
sICH	17 (6.1)	5 (10.2)	0.5 (0.2–1.8)

AdjOR indicates adjusted odds ratio; mRS, modified Rankin Scale; sICH, symptomatic intracranial hemorrhage; and TICI, Thrombolysis in Cerebral Infarction.

*$P<0.0001$.

DISCUSSION

In this study, we analyzed outcome and safety data for patients with AIS treated with EVT beyond 6 hours from witnessed symptom onset in a real-world setting. EVT eligibility was decided by a combination of collateral score and CTP mismatch assessed by visual inspection. A qualitative evaluation of CTP mismatch was used due to the limited availability of automated software programs for a threshold-based calculation of infarct core, ischemic penumbra volumes, and of mismatch ratio (target mismatch) at the time of patient enrollment in Italy. We adopted an integrated approach, including CTA collateral score and CTP mismatch; this approach has recently been demonstrated to be promising for the selection of patient with AIS candidates for reperfusion therapies.[22,23]

Mortality and sICH of patients treated beyond and within the conventional time window were not significantly different, suggesting that patient with AIS treated

later from onset, selected for EVT using the eligibility criteria described above, had safety profiles comparable to patient with AIS treated earlier.

Patients who underwent EVT beyond 6 hours (within 24 hours) from symptom onset had a 27% probability to survive with no or very mild disability and a 41.3% probability of functional independence at 3 months after stroke. These results are similar to those reported from a meta-analysis on individual patients data[8] from 5 RCT trials[1–5] that identified 147 patients with stroke due to LVO of the anterior circulation treated beyond 6 hours either with mechanical thrombectomy (n=77) or with standard medical care (n=70); the proportion of patients surviving with functional independence (mRS, 0–2) was 39% for patients who underwent endovascular treatment and 24.4% in the control (best medical therapy) group. Our findings were also consistent with data from previous observational studies testing the possibility to extend the time window for EVT beyond 6 hours by using advanced brain imaging, including CTP and magnetic resonance diffusion-weighed imaging (MR-DWI) and perfusion-weighted imaging (MR-PWI).[17,24–33] CTP, MR-DWI, and MR-PWI selection criteria were established by visual inspection in all but one[23] of these articles. In one study, advanced imaging was adopted in 34% of patients.[33] In these studies, the number of included patients ranged from 21[25] to 268[2]; the site of occlusion involved anterior circulation[25,26,28–33] and either anterior or posterior circulation;[17,24,27,28] patients were treated beyond 8 hours,[24,26,29,30] beyond 7 hours,[17] beyond 6 hours from symptom onset, or, more frequently, from time last seen well[25,27,28,31–33]; the proportion of patients achieving a good functional outcome (90-day mRS, 0–2) ranged from 32%[31] to 62%,[33] and the case fatality rate ranged from 13% to 26.2% (Table 5). The utility of advanced imaging in the selection of late-presenting patients with AIS with LVO was further confirmed by a recent single-center study showing a good outcome in 36% of patients when those with baseline mRS >2 were excluded.[34]

In our study, the comparison between patients treated within and beyond 6 hours after symptom onset demonstrated that the chance of good clinical outcome declined with longer onset to treatment intervals, without significantly affecting safety outcomes. Recent late windows trials[9,10] showed a favorable outcome rate of 49% and 45%, respectively, similar to that reported by the HERMES Collaboration meta-analysis of early window trials.[7] However, it should be acknowledged that the HERMES study incorporated early window patients selected with CT and CTA without further advanced imaging, leading to the potential inclusion of a proportion of patients with a matched core and penumbra: this could have blunted the differences in outcome between patients treated in the early and late time windows. In fact, in RCTs enrolling patients in early time windows with advanced imaging (EXTEND IA and SWIFT PRIME),[1,3] the rates of good outcome were found to be 71% and 63%, respectively.[35] Therefore, these observations could explain the decrease in good outcomes over time reported in our study in which both early- and late-treated patients were selected with advanced imaging. Additionally, these findings seem to indicate that time remains a key variable in predicting clinical outcome on a population basis, but not at individual level, where it is just one of the many variables affecting outcome, reinforcing the

Table 5. Overview of Observational Studies on EVT Beyond 6 Hours

	No. of Patients	Age*	Baseline NIHSS†	mRS 0–2‡	Death‡	sICH
Natarajan et al[24]	30	72 (range 24–91)	12 (range, 5–22)	33.3	20	10
Abou-Chebl[25]	21	59.4 (17.2)	17.8 (5.5) mean (SD)	43	23.8 (30-day)	9.5
Jovin[26]	169	64 (16)	17 (range 10–29)	40	25	10
Jung[27]	128	61.1 (15.1)	15 (range 2–36)	35.2	26.2	3.7
Turk, 2013[17]	70	64.9	15.1	45.5	21.2	5.6
Abilleira et al[28]	154	65 (14.2)	17 (13–21)	35.7	23.4	8.4
Gratz[29]	22	67.1 (14.5)	16.5 (range 8–22)	36.4	18.2	9.1
Aghaebrahim et al[30]	128	64 (13.6)	14 (5.4) mean (SD)	50	22	5.5§
Tsurukiri et al[31]	31	74 (9)	17 (13–20)	32	13	10
Mokin et al[32]	248	66.1 (14.6)	16 (13–20)	46.2	21.6	11
		69.9 (14)	16 (12–20)			
Alsahli et al[33]	56	72 (60–82)	15 (8–20)	62	14	7
Present study	327	66.8 (14.9)	16 (12–20)	41.3	17.1	6.7

EVT indicates endovascular thrombectomy; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; and sICH, symptomatic intracranial hemorrhage.

*Mean (SD) unless otherwise stated.

†Median (IQR) unless otherwise stated.

‡90-day unless otherwise stated.

§In this study, only data about hemorrhagic transformation PH type was reported.

view that a selection of patients only based on time is no longer justified.[36]

Taken together, the data obtained in the present study suggest the possibility to extend the time window for EVT beyond 6 hours after onset in the real world using a combined approach based on the concomitant visual assessment of CTA collateral extent and CTP mismatch even in those centers not equipped with automated software programs able to calculate the different parameters of target mismatch. Nevertheless, the lack of a control group of untreated patients limits the strength of these findings since it precludes an actual assessment of treatment effect, the comparison with previous RCTs and as a consequence, the generalization of our results.

This study has other limitations, most of which are inherent to its observational nature. First, despite central monitoring of data quality and completeness, it is not possible to exclude reporting biases in a multicenter prospective national registry with self-reported clinical and outcome data. Second, the visual, qualitative interpretation of radiological findings could represent another drawback of the current analysis, since it is now widely accepted that threshold-based quantitative parameters obtained with automated software programs represent the best method for correctly identifying patients with AIS who can benefit from EVT beyond 6 hours after onset.[9,10,12] However, our study showed a safety profile similar to that reported in the setting of clinical trials.[9,10] Although RCTs remain the gold standard in the assessment of intended effects of interventions, observational studies can be useful for providing important information under everyday circumstances.

ARTICLE INFORMATION

Received October 19, 2019; final revision received April 8, 2020; accepted April 27, 2020.

Presented in part at the European Stroke Organisation Conference, Milan, Italy, May 22–24, 2019; the 5th Congress of the Academy of Neurology, Oslo, Norway, June 29–July 2, 2019; and the 50th Congresso della Società Italiana di Neurologia, Bologna, Italy, October 12–15, 2019.

Affiliations

Clinica Neurologica, University of Ferrara, (I.C., M.P.). Neuroradiology Unit, University of Florence (E.F.). Stroke Unit, Santa Corona Hospital, Pietra Ligure (V.S.). Interventional Neuroradiology Unit, Careggi University Hospital, Florence (L.R., S.M.). Stroke Unit, Careggi University Hospital, Florence (G.P., P.N., D.I.). Diagnostic Imaging and Interventional Radiology Unit (D.M.) and Stroke Unit (F.S.), University of Rome Tor Vergata. Interventional Neuroradiology Unit (S.V.) and Stroke Unit (G.B.), Ospedale Civile "S.Agostino-Estense", AOU Modena. Neurology and Stroke Unit, Maggiore Hospital, Bologna (A.Z.). Interventional Neuroradiology Unit, Policlinico G Martino, Messina (M.L.). Stroke Unit, Policlinico G. Martino, Messina (F.I.). Neuroimaging and Neurointervention Unit (NINT), AOU Senese, Siena (S.B., I.M.V.). Stroke Unit, University Hospital "S. Maria delle Scotte", Siena (R.T.). Interventional Neuroradiology Unit, Città della Salute e della Scienza–Molinette, Turin (M.B.). Department of Neuroscience "Rita Levi Montalcini", University of Turin (A.N.). Interventional Neuroradiology Unit, University Hospital "Arcispedale S. Anna", Ferrara (A.S.). Stroke Unit, University Hospital "Arcispedale S. Anna", Ferrara (A.D.V.). Interventional Neuroradiology Unit, "Spedali Civili", Brescia (R.G.). Stroke Unit, "Spedali Civili", Brescia (A.M.). Interventional Neuroradiology Unit, IRCCS San Martino-IST, Genova (L.C.). Neurology and Stroke Unit, IRCCS San Martino-IST, Genova (C.S.). Interventional Neuroradiology Unit (R.M.) and Stroke Unit (U.S.), University Hospital, Parma. Neuroradiology Unit (F.C.) and Stroke Unit and Neurosonology Lab (A.P.), Padua University Hospital. Vascular and Interventional Radiology Unit (E.P.) and Neurology Unit (A.C.), Ospedale Civile "Mazzini", Teramo. Neuroradiology Unit (A.S., M.R.) and Neurology Unit (F.C.). "M. Bufalini" Hospital-AUSL Romagna, Cesena. Interventional Radiology and Neuroradiology Unit (L.D.M) and Neurology Unit (E.D.), San Giovanni Bosco Hospital, Torino. Neuroradiology Unit (M.C.) and Neurology Unit (G.N.), AOU Pisa. Radiology, Diagnostic and Interventional Neuroradiology Unit, Policlinico IRCCS San Matteo, Pavia (G.S., F.Z.). Neuroradiology Unit (N.C.) and Neurology Unit (A.C.), Ospedale dell'Angelo–USSL3 Serenissima, Mestre. Neuroradiology Unit (E.C., M.P.) and Neurology Unit (M.C.), AOUI Verona. Interventional Neuroradiology Unit (L.C.) and Stroke Unit (M.P.), Policlinico Bari. Neuroradiology Unit (A.T.) and Neurology and Stroke Unit (L.P.C.), AOU Circolo, ASST-Settelaghi, Varese. Interventional Radiology (N.B.) and Stroke Unit (A.T.), Ospedale SS. Annunziata, Taranto. Interventional Neuroradiology Unit, AO Annunziata, Cosenza (W.A., U.S.). Interventional Neuroradiology Unit, Policlinico Umberto I, Rome (F.B.). Emergency Department Stroke Unit, Sapienza University Hospital, Rome (E.N., D.T.). Neuroradiology Unit (R.P.) and Neurology and Stroke Unit (T.T.), S. Corona Hospital-ASL2 Savonese, Pietra Ligure. Interventional Neuroradiology Unit, PO SS. Filippo e Nicola, Avezzano (P.F.). Department of Applied Clinical Sciences e Biotechnology, University of L'Aquila, L'Aquila (S.S.). Neuroradiology Unit (M.P.) and Neurology Unit (P.I.), Istituto Ospedaliero Fondazione Poliambulanza, Brescia. Interventional Neuroradiology Unit (N.P.N.) and Urgent Neurology and Stroke Unit (S.M.), Humanitas Research Hospital, Rozzano. Interventional Neuroradiology Unit (P.A.) and Stroke Unit (M.R.), S. Maria della Misericordia Hospital, Rovigo. Neuroradiology Unit, SS. Antonio e Biagio e C. Arrigo Hospital, Alessandria (I.G.). Neuroradiology and Interventional Vascular Unit, AO Brotzu, Cagliari (S.C.). Interventional Neuroradiology Unit (G.C.) and Stroke Unit (M.M.), Ospedale Civico-A.R.N.A.S., Palermo.

Sources of Funding

The project Registro Nazionale Trattamento Ictus Acuto (RFPS-2006-1-336562) was funded by grants from the Italian Ministry of Health within the framework of 2006 Finalized Research Programmes (D.Lgs.n.502/1992).

Disclosures

Dr Bergui received consulting fees from Stryker Italia and Penumbra Inc. Dr Cavasin received consulting fees from Microvention Europe and Acandis GmbH. Dr De Vito received consulting fees from Boehringer-Ingelheim, and Daiichi Sankyo. Dr Inzitari received research grants and speaker honoraria from Shire Italia. Dr Sacco reports personal fees and nonfinancial support from Allergan, Abbott, Eli Lilly, Novartis, TEVA, personal fees from Medscape, Bayer, Pfizer, Medtronic, Starmed, Bristol-Myers Squibb, and from Daiichi-Sankyo outside the submitted work. Dr Nuzzi received consulting fees from Penumbra Inc. and Acandis. Dr Zini received speaker and consulting fees from Boehringer-Ingelheim, Medtronic, and Cerenovus and serves as advisory board for Daiichi Sankyo, Boehringer-Ingelheim and Stryker. Dr Sanfilippo received nonfinancial support from Bracco, Medtronic, and Penumbra Inc. Dr Mangiafico acted as a consultant for Cerenovus. Dr Toni received honoraria as a member of advisory board of Abbott, Boehringer Ingelheim, Bayer, Pfizer-BMS, Medtronic, and Daiichi Sankyo. The other authors report no conflicts.

REFERENCES

1. Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, Yan B, Dowling RJ, Parsons MW, Oxley TJ, et al; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Engl J Med*. 2015;372:1009–1018. doi: 10.1056/NEJMoa1414792
2. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, Roy D, Jovin TG, Willinsky RA, Sapkota BL, et al; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. *N Engl J Med*. 2015;372:1019–1030. doi: 10.1056/NEJMoa1414905
3. Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, Albers GW, Cognard C, Cohen DJ, Hacke W, et al; SWIFT PRIME Investigators. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. *N Engl J Med*. 2015;372:2285–2295. doi: 10.1056/NEJMoa1415061
4. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, Schonewille WJ, Vos JA, Nederkoorn PJ, Wermer MJH, et al; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med*. 2015;372:11–20. doi: 10.1056/NEJMoa1411587
5. Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, Román LS, Serena J, Abilleira S, Ribó M, et al; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. *N Engl J Med*. 2015;372:2296–2306. doi: 10.1056/NEJMoa1503780

6. Bracard S, Ducrocq X, Mas JL, Soudant M, Oppenheim C, Moulin T, Guillemin F; THRACE investigators. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. *Lancet Neurol*. 2016;15:1138–1147. doi: 10.1016/S1474-4422(16)30177-6
7. Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, Dávalos A, Majoie CBLM, van der Lugt A, de Miquel MA, et al; HERMES collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet*. 2016;387:1723–1731. doi: 10.1016/S0140-6736(16)00163-X
8. Saver JL, Goyal M, van der Lugt A, Menon BK, Majoie CB, Dippel DW, Campbell BC, Nogueira RG, Demchuk AM, Tomasello A, et al; HERMES Collaborators. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. *JAMA*. 2016;316:1279–1288. doi: 10.1001/jama.2016.13647
9. Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, McTaggart RA, Torbey MT, Kim-Tenser M, Leslie-Mazwi T, et al; DEFUSE 3 Investigators. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. *N Engl J Med*. 2018;378:708–718. doi: 10.1056/NEJMoa1713973
10. Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, Yavagal DR, Ribo M, Cognard C, Hanel RA, et al; DAWN Trial Investigators. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. *N Engl J Med*. 2018;378:11–21. doi: 10.1056/NEJMoa1706442
11. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, et al; American Heart Association Stroke Council. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2018;49:e46–e110. doi: 10.1161/STR.0000000000000158
12. Turc G, Bhogal P, Fischer U, Khatri P, Lobotesis K, Mazighi M, Schellinger PD, Toni D, de Vries J, White P, et al. European Stroke Organisation (ESO)-European Society for Minimally Invasive Neurological Therapy (ESMINT) guidelines on mechanical thrombectomy in acute ischemic stroke. *J Neurointerv Surg*. 2019;11:535–538. doi: 10.1136/neurintsurg-2018-014568
13. Mangiafico S, Pracucci G, Saia V, Nencini P, Inzitari D, Nappini S, Vallone S, Zini A, Fuschi M, Cerone D, et al. The Italian Registry of Endovascular Treatment in Acute Stroke: rationale, design and baseline features of patients. *Neurol Sci*. 2015;36:985–993. doi: 10.1007/s10072-014-2053-5
14. Casetta I, Pracucci G, Saletti A, Saia V, Padroni M, De Vito A, Inzitari D, Zini A, Vallone S, Bergui M, et al; The Italian Registry of Endovascular Treatment in Acute Stroke. Combined intravenous and endovascular treatment versus primary mechanical thrombectomy. The Italian Registry of Endovascular Treatment in Acute Stroke. *Int J Stroke*. 2019;14:898–907. doi: 10.1177/1747493019851279
15. SPREAD (Stroke Prevention and Educational Awareness Diffusion). Italian Guidelines For Stroke Prevention And Management. 8th ed. http://isospread.it. Accessed January 5, 2020.
16. Tan IY, Demchuk AM, Hopyan J, Zhang L, Gladstone D, Wong K, Martin M, Symons SP, Fox AJ, Aviv RI. CT angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct. *AJNR Am J Neuroradiol*. 2009;30:525–531. doi: 10.3174/ajnr.A1408
17. Menon BK, d'Esterre CD, Qazi EM, Almekhlafi M, Hahn L, Demchuk AM, Goyal M. Multiphase CT angiography: a new tool for the imaging triage of patients with acute ischemic stroke. *Radiology*. 2015;275:510–520. doi: 10.1148/radiol.15142256
18. Wintermark M, Flanders AE, Velthuis B, Meuli R, van Leeuwen M, Goldsher D, Pineda C, Serena J, van der Schaaf I, Waaijer A, et al. Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. *Stroke*. 2006;37:979–985. doi: 10.1161/01.STR.0000209238.61459.39
19. Turk A, Magarik JA, Chaudry I, Turner RD, Nicholas J, Holmstedt CA, Chalela J, Hays A, Lazaridis C, Jauch E, et al. CT perfusion-guided patient selection for endovascular treatment of acute ischemic stroke is safe and effective. *J Neurointerv Surg*. 2012;4:261–265. doi: 10.1136/neurintsurg-2011-010067
20. Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, et al; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. *Stroke*. 2003;34:e109–e137. doi: 10.1161/01.STR.0000082721.62796.09
21. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. *Lancet*. 1998;352:1245–1251. doi: 10.1016/s0140-6736(98)08020-9
22. Vagal A, Menon BK, Foster LD, Livorine A, Yeatts SD, Qazi E, d'Esterre C, Shi J, Demchuk AM, Hill MD, et al. Association between CT angiogram collaterals and CT perfusion in the interventional management of stroke III trial. *Stroke*. 2016;47:535–538. doi: 10.1161/STROKEAHA.115.011461
23. Bivard A, Levi C, Lin L, Cheng X, Aviv R, Spratt NJ, Lou M, Kleinig T, O'Brien B, Butcher K, et al. Validating a predictive model of acute advanced imaging biomarkers in ischemic stroke. *Stroke*. 2017;48:645–650. doi: 10.1161/STROKEAHA.116.015143
24. Natarajan SK, Snyder KV, Siddiqui AH, Ionita CC, Hopkins LN, Levy EI. Safety and effectiveness of endovascular therapy after 8 hours of acute ischemic stroke onset and wake-up strokes. *Stroke*. 2009;40:3269–3274. doi: 10.1161/STROKEAHA.109.555102
25. Abou-Chebl A. Endovascular treatment of acute ischemic stroke may be safely performed with no time window limit in appropriately selected patients. *Stroke*. 2010;41:1996–2000. doi: 10.1161/STROKEAHA.110.578997
26. Jovin TG, Liebeskind DS, Gupta R, Rymer M, Rai A, Zaidat OO, Abou-Chebl A, Baxter B, Levy EI, Barreto A, et al. Imaging-based endovascular therapy for acute ischemic stroke due to proximal intracranial anterior circulation occlusion treated beyond 8 hours from time last seen well: retrospective multicenter analysis of 237 consecutive patients. *Stroke*. 2011;42:2206–2211. doi: 10.1161/STROKEAHA.110.604223
27. Jung S, Gralla J, Fischer U, Mono ML, Weck A, Lüdi R, Heldner MR, Findling O, El-Koussy M, Brekenfeld C, et al. Safety of endovascular treatment beyond the 6-h time window in 205 patients. *Eur J Neurol*. 2013;20:865–871. doi: 10.1111/ene.12069
28. Abilleira S, Cardona P, Ribó M, Millán M, Obach V, Roquer J, Cánovas D, Martí-Fàbregas J, Rubio F, Alvarez-Sabín J, et al; Catalan Stroke Code and Reperfusion Consortium. Outcomes of a contemporary cohort of 536 consecutive patients with acute ischemic stroke treated with endovascular therapy. *Stroke*. 2014;45:1046–1052. doi: 10.1161/STROKEAHA.113.003489
29. Gratz PP, Jung S, Schroth G, Gralla J, Mordasini P, Hsieh K, Heldner MR, Mattle HP, Mono M-L, Fischer U, et al. Outcome of standard and high-risk patients with acute anterior circulation stroke after stent retriever thrombectomy. *Stroke*. 2014;45:152–158. doi: 10.1161/STROKEAHA.113.002591
30. Aghaebrahim A, Leiva-Salinas C, Jadhav AP, Jankowitz B, Zaidi S, Jumaa M, Urra X, Amorim E, Zhu G, Giurgiutiu D-V, et al. Outcomes after endovascular treatment for anterior circulation stroke presenting as wake-up strokes are not different than those with witnessed onset beyond 8 hours. *J Neurointerv Surg*. 2015;7:875–880. doi: 10.1136/neurintsurg-2014-011316
31. Tsurukiri J, Ota T, Jimbo H, Okumura E, Shigeta K, Amano T, Ueda M, Matsumaru Y, Shiokawa Y, Hirano T. Thrombectomy for stroke at 6-24 hours without perfusion CT software for patient selection. *J Stroke Cerebrovasc Dis*. 2019;28:774–781. doi: 10.1016/j.jstrokecerebrovasdis.2018.11.022
32. Mokin M, Abou-Chebl A, Castonguay AC, Nogueira RG, English JD, Farid H, Gupta R, Martin C, Holloway WE, Haussen DC, et al; NASA and TRACK investigators. Real-world stent retriever thrombectomy for acute ischemic stroke beyond 6 hours of onset: analysis of the NASA and TRACK registries. *J Neurointerv Surg*. 2019;11:334–337. doi: 10.1136/neurintsurg-2018-014272
33. Alsahli K, Cheung AK, Wijesuriya N, Cordato D, Zagami AS, Wenderoth JD, Chiu AH, Tay K, Cappelen-Smith C. Thrombectomy in stroke of unknown onset, wake up stroke and late presentations: Australian experience from 2 comprehensive stroke centres. *J Clin Neurosci*. 2019;59:136–140. doi: 10.1016/j.jocn.2018.10.114
34. Jadhav AP, Desai SM, Kenmuir CL, Rocha M, Starr MT, Molyneaux BJ, Gross BA, Jankowitz BT, Jovin TG. Eligibility for endovascular trial enrollment in the 6- to 24-hour time window: analysis of a single comprehensive stroke center. *Stroke*. 2018;49:1015–1017. doi: 10.1161/STROKEAHA.117.020273
35. Albers GW. Late window paradox. *Stroke*. 2018;49:768–771. doi: 10.1161/STROKEAHA.117.020200
36. von Kummer R. Treatment of ischemic stroke beyond 3 hours: is time really brain? *Neuroradiology*. 2019;61:115–117. doi: 10.1007/s00234-018-2122-1